{
    "nctId": "NCT04792840",
    "briefTitle": "Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer",
    "officialTitle": "Lymphedema and Skeletal Events in Older Patients Receiving Adjuvant Hormonal and Radiotherarpy in Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Skeletal events caused by hermonal treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal patients with positive diagnosis of stage 1-3 breast cancer and planned AI (anastrazole, letrozole) adjuvant treatment will be included in the study.\n* Patients without known osteoporosis will included in the study, and before AI treatment began.\n* Conventional RT course must be completed (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week).\n* Patients continue to receive adjuvant hormonal treatment (aromatase inhibitors) or adjuvant target therapy (trastuzumab) while monitoring late toxicities\n\nExclusion Criteria:\n\n* Male patients\n* Metastatic disease at presentation\n* No definitive surgery\n* Carcinoma in situ or other rare tumors of the breast as phyllodes tumors.",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}